van Drunen Littel-van den Hurk S, Gifford G A, Babiuk L A
Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
Vaccine. 1990 Aug;8(4):358-68. doi: 10.1016/0264-410x(90)90095-4.
Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.
将亲和纯化的牛疱疹病毒1型（BHV-1）糖蛋白gI、gIII和gIV，以及无病毒的BHV-1感染细胞裂解物肌肉注射到血清阴性的犊牛体内。使用BHV-1/溶血巴斯德菌攻毒模型，所有免疫动物均产生了特异性血清中和抗体，并且完全受到疾病保护。攻毒后，用gIV（10000倍）或BHV-1感染细胞裂解物（450000倍）免疫的动物鼻道中的病毒复制显著减少，但用gI（500倍）或gIII（25倍）免疫的动物仅略有减少。在亲和纯化或制备细胞裂解物过程中，糖蛋白的所有已知表位均得以保留。特别是gIV和病毒感染细胞裂解物诱导的高水平保护表明，糖蛋白gIV作为亚单位疫苗具有潜力，理想情况下可与细胞裂解物中的成分联合使用，后者可能介导细胞免疫反应。
